A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Human Vaccines & Immunotherapeutics

• Publication date

  2016-03-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1080/21645515.2015.1119346PMID 26890466PMCID PMC4962947
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chagas disease in Latin America: an epidemiological update based on 2010 estimates.

  2015cited by this paper
• A Human Type 5 Adenovirus-Based Trypanosoma cruzi Therapeutic Vaccine Re-programs Immune Response and Reverses Chronic Cardiomyopathy

  2015cited by this paper
• Usefulness of real time PCR to quantify parasite load in serum samples from chronic Chagas disease patients

  2015cited by this paper
• Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in mice.

  2015cited by this paper
• Chagas' Disease.

  2015cited by this paper
• A Two-Component DNA-Prime/Protein-Boost Vaccination Strategy for Eliciting Long-Term, Protective T Cell Immunity against Trypanosoma cruzi

  2015cited by this paper
• Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

  2015cited by this paper
• Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy.

  2015cited by this paper
• Global, regional, and national incidence, prevalence, and YLDs for 301 acute and chronic diseases and injuries for 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013

  2015cited by this paper
• New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice.

  2014cited by this paper
• Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.

  2014cited by this paper
• Global economic burden of Chagas disease: a computational simulation model.

  2013cited by this paper
• PLGA nanoparticles loaded with KMP-11 stimulate innate immunity and induce the killing of Leishmania.

  2013cited by this paper
• TcVac3 Induced Control of Trypanosoma cruzi Infection and Chronic Myocarditis in Mice

  2013cited by this paper
• Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome® in mice infected with Trypanosoma cruzi strains.

  2012cited by this paper
• Chagas Heart Disease

  2012cited by this paper
• Chagas Disease in Non-Endemic Countries: Epidemiology, Clinical Presentation and Treatment

  2012cited by this paper
• Modeling the economic value of a Chagas’ disease therapeutic vaccine

  2012cited by this paper
• Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects

  2012cited by this paper
• Real-time PCR strategy for parasite quantification in blood and tissue samples of experimental Trypanosoma cruzi infection.

  2012cited by this paper
• Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8(+)T cell mediated immunity against Trypanosoma cruzi.

  2012cited by this paper
• Targeting of Toll-like receptors: a decade of progress in combating infectious diseases.

  2011cited by this paper
• Parasitic Loads in Tissues of Mice Infected with Trypanosoma cruzi and Treated with AmBisome

  2011cited by this paper
• A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease.

  2010cited by this paper
• Effect of a combination DNA vaccine for the prevention and therapy of Trypanosoma cruzi infection in mice: role of CD4+ and CD8+ T cells.

  2010cited by this paper
• Chagas disease.

  2010cited by this paper
• Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses

  2010influential reference
• Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins.

  2010cited by this paper
• Prophylactic Efficacy of TcVac2 against Trypanosoma cruzi in Mice

  2010cited by this paper
• The optimization of TaqMan real-time RT-PCR assay for transcriptional profiling of GABA-A receptor subunit plasticity.

  2009cited by this paper
• Current advances in research and clinical applications of PLGA-based nanotechnology

  2009cited by this paper
• Chagas heart disease: pathophysiologic mechanisms, prognostic factors and risk stratification.

  2009cited by this paper
• Innovative strategies for co-delivering antigens and CpG oligonucleotides.

  2009cited by this paper
• The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles.

  2008cited by this paper
• Comparative evaluation of therapeutic DNA vaccines against Trypanosoma cruzi in mice.

  2007cited by this paper
• Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester

  2007cited by this paper
• Evaluation and treatment of chagas disease in the United States: a systematic review.

  2007cited by this paper
• Development of a real-time PCR assay for Trypanosoma cruzi detection in blood samples.

  2007cited by this paper
• Therapeutic potential of Toll-like receptor 9 activation

  2006cited by this paper
• Distinct Kinetics of Effector CD8+ Cytotoxic T Cells after Infection with Trypanosoma cruzi in Naïve or Vaccinated Mice

  2006cited by this paper
• In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles.

  2006cited by this paper
• Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

  2005cited by this paper
• Immunotherapy of Trypanosoma cruzi Infection with DNA Vaccines in Mice

  2004cited by this paper
• Frequency of interferon- gamma -producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease.

  2004cited by this paper
• Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors1

  2004cited by this paper
• Aluminium compounds for use in vaccines

  2004cited by this paper
• Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery.

  2004cited by this paper
• Therapeutic Vaccines for Chronic Infections

  2004cited by this paper
• A single vaccination with protein-microspheres elicits a strong CD8 T-cell-mediated immune response against Mycobacterium tuberculosis antigen Mtb8.4.

  2004cited by this paper
• Infection with Dna Vaccines in Mice

  2003cited by this paper
• Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro.

  2003cited by this paper
• Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres.

  2002cited by this paper
• Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells.

  2001cited by this paper
• Chagas' Heart Disease

  2000cited by this paper
• CpG-DNA Activates In Vivo T Cell Epitope Presenting Dendritic Cells to Trigger Protective Antiviral Cytotoxic T Cell Responses1

  2000cited by this paper
• The targets of the lytic antibody response against Trypanosoma cruzi.

  2000cited by this paper
• Parasite persistence correlates with disease severity and localization in chronic Chagas' disease.

  1999cited by this paper
• A new strategy to determine the actual protein content of poly(lactide-co-glycolide) microspheres.

  1997cited by this paper
• Homologues of the 24-kDa flagellar Ca(2+)-binding protein gene of Trypanosoma cruzi are present in other members of the Trypanosomatidae family.

  1997cited by this paper
• Use of a recombinant Trypanosoma cruzi protein antigen to monitor cure of Chagas disease.

  1995cited by this paper
• Utility of recombinant flagellar calcium-binding protein for serodiagnosis of Trypanosoma cruzi infection

  1995cited by this paper
• Trypanosoma cruzi: analysis of cellular and humoral response against a protective recombinant antigen during experimental Chagas' disease.

  1995cited by this paper
• Depletion of T-cell subpopulations results in exacerbation of myocarditis and parasitism in experimental Chagas' disease

  1994cited by this paper
• Trypanosoma cruzi: immunity-induced in mice and rats by trypomastigote excretory-secretory antigens and identification of a peptide sequence containing a T cell epitope with protective activity.

  1993cited by this paper
• Complement-mediated lysis of Trypanosoma cruzi trypomastigotes by human anti-alpha-galactosyl antibodies.

  1991cited by this paper
• Depletion of CD8+ T cells increases susceptibility and reverses vaccine-induced immunity in mice infected with Trypanosoma cruzi.

  1990cited by this paper
• A novel flagellar Ca2+-binding protein in trypanosomes.

  1989cited by this paper

• Epitope mapping of vaccine antigens Tc24 and TSA1 with antibodies from Trypanosoma cruzi-infected patients.

  2026cites this paper
• Epitope mapping of vaccine antigens Tc24 and TSA1 with antibodies from Trypanosoma cruzi infected patients

  2025cites this paper
• Advancements, Challenges, and Future Prospects of Nanotechnology in Sepsis Therapy

  2025cites this paper
• Randomized field trial of a therapeutic vaccine against Trypanosoma cruzi natural infection in dogs and correlates for efficacy

  2025cites this paper
• Immunotherapeutic efficacy of Th1 stimulatory epitopes derived from Leishmania donovani enolase and triose phosphatase isomerase in experimental visceral leishmaniasis.

  2025cites this paper
• An Update on Vaccines Against Trypanosoma cruzi and Chagas Disease

  2025cites this paper
• Immunomodulatory activity of Trypanosoma cruzi recombinant antigen combination TSA-1-C4 and Tc24-C4 induce activation of macrophages and CD8+ T cells

  2025cites this paper
• Randomized field trial of a therapeutic vaccine against Trypanosoma cruzi natural infection in dogs and correlates for efficacy

  2025cites this paper
• Alternative Approaches for the Treatment of Chagas Disease

  2024cites this paper
• Microalgae‐made human vaccines and therapeutics: A decade of advances

  2024cites this paper
• Chagas Disease: A Silent Threat for Dogs and Humans

  2024cites this paper
• Challenges and advancements in the development of vaccines and therapies against Chagas disease.

  2024cites this paper
• Development and Application of an Assay to Evaluate the Anti-Parasitic Effect of Humoral Responses against Trypanosoma cruzi

  2023cites this paper
• Protective efficacy of the oral vaccine Tc24:Co1 produced in Schizochytrium sp. against Trypanosoma cruzi infection in a mouse model.

  2023cites this paper
• Nanotechnology-Based Strategies in Parasitic Disease Management: From Prevention to Diagnosis and Treatment

  2023cites this paper
• Bibliometric analysis of parasite vaccine research from 1990 to 2019.

  2023cites this paper
• Heterologous mRNA-protein vaccination with Tc24 induces a robust cellular immune response against Trypanosoma cruzi, characterized by an increased level of polyfunctional CD8+ T-cells

  2023cites this paper
• Trypanosoma cruzi Tc24 Antigen Expressed and Orally Delivered by Schizochytrium sp. Microalga is Immunogenic in Mice

  2023cites this paper
• Exploring the performance of Escherichia coli outer membrane vesicles as a tool for vaccine development against Chagas disease

  2023cites this paper
• Vaccine-linked chemotherapy improves cardiac structure and function in a mouse model of chronic Chagas disease

  2023influential citation
• Vaccine-linked chemotherapy with a low dose of benznidazole plus a bivalent recombinant protein vaccine prevents the development of cardiac fibrosis caused by Trypanosoma cruzi in chronically-infected BALB/c mice

  2022cites this paper
• Comparing in vivo bioluminescence imaging and the Multi-Cruzi immunoassay platform to develop improved Chagas disease diagnostic procedures and biomarkers for monitoring parasitological cure

  2022cites this paper
• Safety and preservation of cardiac function following therapeutic vaccination against Trypanosoma cruzi in rhesus macaques

  2022cites this paper
• Pathogen diversity, immunity, and the fate of infections: lessons learned from Trypanosoma cruzi human-host interactions.

  2022cites this paper
• Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine

  2022influential citation
• Protective immunity triggered by ectonucleoside triphosphate diphosphohydrolase-based biopharmaceuticals attenuates cardiac parasitism and prevents mortality in Trypanosoma cruzi infection.

  2022cites this paper
• The Case for the Development of a Chagas Disease Vaccine: Why? How? When?

  2021cites this paper
• Vaccine-linked chemotherapy induces IL-17 production and reduces cardiac pathology during acute Trypanosoma cruzi infection

  2021cites this paper
• Plant-made vaccines against parasites: bioinspired perspectives to fight against Chagas disease

  2021cites this paper
• Role of biomaterials in the diagnosis, prevention, treatment, and study of corona virus disease 2019 (COVID-19)

  2021cites this paper
• Nano-Medicines a Hope for Chagas Disease!

  2021cites this paper
• Protozoal and Rickettsial Vaccines

  2021cites this paper
• α-Gal immunization positively impacts Trypanosoma cruzi colonization of heart tissue in a mouse model

  2021cites this paper
• Oxidative stress implications for therapeutic vaccine development against Chagas disease

  2021cites this paper
• Signal Transducer and Activator of Transcription-3 Modulation of Cardiac Pathology in Chronic Chagasic Cardiomyopathy

  2021cites this paper
• Location and expression kinetics of Tc24 in different life stages of Trypanosoma cruzi

  2021cites this paper
• Nanovaccine: an emerging strategy

  2021influential citation
• Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks

  2020cites this paper
• Chagas disease vaccine design: the search for an efficient Trypanosoma cruzi immune-mediated control.

  2020cites this paper
• Reproductive Outcomes in Rhesus Macaques (Macaca mulatta) with Naturally-acquired Trypanosoma cruzi Infection.

  2020cites this paper
• Bioengineered in Vitro Tissue Models to Study SARS-CoV-2 Pathogenesis and Therapeutic Validation

  2020cites this paper
• Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine Against Trypanosoma cruzi

  2020cites this paper
• Alterations to the cardiac metabolome induced by chronic T. cruzi infection relate to the degree of cardiac pathology

  2020cites this paper
• Safety and immunogenicity of a recombinant vaccine against Trypanosoma cruzi in Rhesus macaques.

  2020cites this paper
• Understanding CD8+ T cell immunity to T. cruzi and how to improve it

  2019cites this paper
• Improved Biomarker and Imaging Analysis for Characterizing Progressive Cardiac Fibrosis in a Mouse Model of Chronic Chagasic Cardiomyopathy

  2019cites this paper
• Understanding CD8+ T Cell Immunity to Trypanosoma cruzi and How to Improve It.

  2019cites this paper
• Immunity and vaccine development efforts against Trypanosoma cruzi.

  2019cites this paper
• Advances in nanocarriers as drug delivery systems in Chagas disease

  2019cites this paper
• A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection

  2019cites this paper
• Evaluation of pathogen P21 protein as a potential modulator of the protective immunity induced by Trypanosoma cruzi attenuated parasites

  2019cites this paper
• Economic value of a therapeutic Chagas vaccine for indeterminate and Chagasic cardiomyopathy patients.

  2019cites this paper
• Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease

  2018cites this paper
• Immunotherapeutic potential of Leishmania (Leishmania) donovani Th1 stimulatory proteins against experimental visceral leishmaniasis.

  2018cites this paper
• Production of recombinant TSA-1 and evaluation of its potential for the immuno-therapeutic control of Trypanosoma cruzi infection in mice

  2018cites this paper
• Trypanosoma cruzi vaccine candidate antigens Tc24 and TSA-1 recall memory immune response associated with HLA-A and -B supertypes in Chagasic chronic patients from Mexico

  2018cites this paper
• 3M-052 as an adjuvant for a PLGA microparticle-based Leishmania donovani recombinant protein vaccine.

  2018cites this paper
• Mutations to Cysteine Residues in the Trypanosoma cruzi B-Cell Superantigen Tc24 Diminish Susceptibility to IgM-Mediated Hydrolysis

  2017cites this paper
• Characterization and Stability of Trypanosoma cruzi 24-C4 (Tc24-C4), a Candidate Antigen for a Therapeutic Vaccine Against Chagas Disease.

  2017cites this paper
• Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease

  2017cites this paper
• Genetic Adjuvantation of a Cell-Based Therapeutic Vaccine for Amelioration of Chagasic Cardiomyopathy

  2017cites this paper
• RECENT ADVANCES ON RECOMBINANT ANTIGENS FOR CONTROLLING PARASITIC PROTOZOA: DIAGNOSIS AND VACCINE DESIGN

  2016cites this paper
• Targeting Pattern Recognition Receptors (PRRs) in Nano- Adjuvants: Current Perspectives

  2016cites this paper